What You Should Know:
– OrganOx, a United Kingdom-based medical technology company committed to making every donated organ count with metra®, a fully automated normothermic machine perfusion (NMP) device for liver transplantation raises £25M ($32.6M USD) in a growth round led by Lauxera Capital Partners (“Lauxera”) with support from existing investors.
– The proceeds from the funding will enable OrganOx to significantly expand its commercial footprint across strategically key areas of the business. This includes expanding the customer-facing team in the United States due to high interest and adoption of the OrganOx technology.
Increasing the Number of Donors Available for Transplant
Based in Oxford, UK, OrganOx is a world leader in normothermic machine perfusion dedicated to saving lives by making every donated organ count. The multi-award-winning OrganOx metra uses proprietary NMP technology to preserve donor livers in a functioning state for up to 24 hours prior to transplant. metra is a fully automated NMP device that enables continuous monitoring and evaluation of the liver, empowering surgeons to make evidence-based decisions on whether to transplant a donor organ, enabling viability testing and transplant of previously declined organs. metra is commercially available in Europe (CE Mark) and the United States (FDA Approved: P200035).
Expansion Plans
In addition, investment will be made in new infrastructure in both the UK and the US over the coming months to facilitate and accelerate programs within the R&D pipeline, some of which will address large and underserved markets adjacent to liver transplantation.
